HB-200 is in a phase 1/2 clinical trial for treatment-refractory HPV16 + cancers and in a phase 2 combination clinical trial with pembrolizumab for head and neck squamous cell carcinomas (HNSCCs).

Additional risk factors that can increase your chances of getting head and neck squamous cell carcinoma include: Occupational hazards such as nickel and wood dust, and the use of chewing tobacco, ...